Abstract
Background and Objectives
Subjects and Methods
Results
Conclusion
Figures and Tables
Fig. 1
![kcj-42-173-g001](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-g001.jpg)
Fig. 2
![kcj-42-173-g002](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-g002.jpg)
Fig. 3
![kcj-42-173-g003](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-g003.jpg)
Table 1
![kcj-42-173-i001](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-i001.jpg)
*ICMP vs. NICMP. NICMP: non-ischemic cardiomyopathy, ICMP: ischemic cardiomyopathy, SD: standard deviation, F/U: follow-up, EF: ejection fraction, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, HMG-CoA: hydroxymethylglutaryl CoA
Table 3
![kcj-42-173-i003](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-i003.jpg)
*Adjusted with age (>70 years old), sex, EF, ICMP, atrial fibrillation, HTN, DM, renal disease, valvular heart disease, beta-blockers, ACEI or ARB, amiodarone, digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and anticoagulation. CI: confidence interval, EF: ejection fraction, ICMP: ischemic cardiomyopathy, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, HMG-CoA: hydroxymethylglutaryl CoA
Table 4
![kcj-42-173-i004](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-i004.jpg)
*Adjusted with age (>70 years old), sex, EF, ICMP, atrial fibrillation, HTN, DM, renal disease, valvular heart disease, beta-blockers, ACEI or ARB, amiodarone, digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and anticoagulation. CI: confidence interval, EF: ejection fraction, ICMP: ischemic cardiomyopathy, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, HMG-CoA: hydroxymethylglutaryl CoA
Table 5
![kcj-42-173-i005](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-i005.jpg)
*Adjusted with age (>70 years old), sex, EF, revascularization, previous myocardial infarction, atrial fibrillation, HTN, DM, renal disease, valvular heart disease, beta-blockers, ACEI or ARB, amiodarone, digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and anticoagulation. †Adjusted with age (>70 years old), sex, EF, revascularization, previous myocardial infarction, atrial fibrillation, HTN, DM, renal disease, beta-blockers, ACEI or ARB, amiodarone, digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and anticoagulation. CI: confidence interval, EF: ejection fraction, ICMP: ischemic cardiomyopathy, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, HMG-CoA: hydroxymethylglutaryl CoA
Table 6
![kcj-42-173-i006](/upload/SynapseData/ArticleImage/0054kcj/kcj-42-173-i006.jpg)
LVEF improvement: improvement of >25% in the LV systolic function compared to the baseline. *p estimated by chi-square methods except classification of deaths, †p estimated by Kaplan-Meier curve and log-rank test. ICMP: ischemic cardiomyopathy, SD: standard deviation, F/U: follow-up, EF: ejection fraction, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, LVEF: left ventricular ejection fraction